About MMC Laboratories

With growing awareness of the medicinal benefits of cannabis and cannabis-derived medicinal products internationally, numerous marketing opportunities were created for which a trustworthy and competent active pharmaceutical ingredient (API) (drug substance) manufacturer is needed.

This led to the establishment of MMC Laboratories in September 2022. With the knowledge and experience gained over many years in the cannabis and pharmaceutical industries by our international leadership team, we took up the task of being this trustworthy manufacturer of quality cannabis-derived APIs and based our manufacturing facility in Lilongwe, Malawi.

Read More
scientist checking hemp plants in a weed greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceptical industry

MMC Laboratories Products for 2025

  • Bulk Cannabis flos to European Pharmacopeial Standards (07/2024:3028)

  • CBD Isolate to German Pharmacopoeia standard

  • THCV Distillate to EU-GMP standard

  • CBG, CBN and CBT as Pharmaceutical grade ingredients from EU-GMP Facility

Science_image_square3

MMC Laboratories at a Glance

API manufacturing in our EudraLex Volume 4 Part II compliant facility
Cultivation to Extraction on a single campus
EU-GaCP compliant cultivation
EU-GMP compliant processing
EU-GMP compliant APIs
CO2 Primary Extraction
Chromatographic isolation of cannabinoids
600 Kg monthly production
European stock holding
European batch release
European distribution
Portrait of scientist with mask checking hemp plants in a greenhouse. Concept of herbal alternative medicine, CBD cannabis oil.